Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial - Galle, PR; Finn, RS; Qin, S (Lancet Oncol, 2021)